Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8739624 | Journal of Autoimmunity | 2017 | 10 Pages |
Abstract
In juvenile patients the identification of a myositis specific autoantibody is highly suggestive of myositis. Autoantibodies can be identified in the majority of affected children and provide useful prognostic information. There is evidence of a differential treatment approach and patients with anti-TIF1γ autoantibodies are significantly more likely to receive aggressive treatment with IV cyclophosphamide and/or biologic drugs, clear trends are also visible in other autoantibody subgroups.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Sarah L. Tansley, Stefania Simou, Gavin Shaddick, Zoe E. Betteridge, Beverley Almeida, Harsha Gunawardena, Wendy Thomson, Michael W. Beresford, Angela Midgley, Francesco Muntoni, Lucy R. Wedderburn, Neil J. McHugh,